Navigation Links
Novel antiviral technology inhibits RSV infection in mice

A novel antiviral treatment combining nanoparticle and gene silencing technologies thwarts attacks of respiratory syncytial virus (RSV) -- a virus associated with severe bronchitis and asthma, an animal study by University of South Florida researchers found. The study was reported in the January 2005 issue of the journal Nature Medicine. RSV infects lung cells and can be life-threatening in very young children, the elderly and those with compromised immune systems. No vaccine or widespread antiviral treatment is available for the infection.

Researchers at USF's Joy McCann Culverhouse Airway Disease Research Center, working with scientists from the Moffitt Cancer Center and TransGenex Nanobiotech Inc., used a revolutionary new technology known as RNA interference, or gene silencing, to knock out one of the key proteins needed for RSV to multiply in the lungs. The virus harnesses this protein, known as NS1, to block the body's own antiviral response, which would normally kill RSV before it could gain a foothold. "This is an exciting advance in the fight against respiratory syncytial virus infection," said Shyam S. Mohapatra, PhD, principal investigator of the study and director of basic research at the USF Division of Allergy and Immunology. "We found that RNA interference targeting a virus's NS1 gene can be administered in the form of a nasal drop or spray. The treatment keeps the host's natural antiviral shield intact and attenuates virus reproduction, providing substantial protection from severe infections over days to weeks." Dr. Mohapatra and his team developed nose drops containing vectors capable of producing small fragments of RNA (siRNA). These fragments were encapsulated within chitosan nanoparticles -- miniscule naturally-occurring, biodegradable particles that stick to mucous-producing cells lining the lungs. The RNA produced is specifically designed to suppress the protein NS1. Without NS1, the host antiviral defense remains intact and the virus ca nnot reproduce. Mice treated intranasally with the gene-silencing nanoparticles, before and after infection with RSV, showed significantly lower levels of virus in the lung and less airway inflammation and hyper-reactivity than untreated mice.


Related biology news :

1. Novel Asthma Study Shows Multiple Genetic Input Required; Single-gene Solution Shot Down
2. Novel technology detects human DNA mutations
3. Novel Enzyme Shows Potential As An Anti-HIV Target
4. Novel Therapy Tested in Mice Could Chase Away Cat Allergies
5. Discovery Could Lead To Novel Approaches In HIV Treatment
6. Novel ultrafast laser detection of cancer cells also may improve understanding of stem cells
7. Research Using Mouse Models Reveals A Novel Key Player In The Initiation Of Colon Cancer
8. Novel gene-silencing nanoparticles shown to inhibit Ewings sarcoma
9. Novel live reporting system to track cells
10. Field of beams - Novel system uses polarized light pulses to reveal crop health
11. Novel compounds show promise as safer, more potent insecticides

Post Your Comments:

(Date:6/22/2016)... , June 22, 2016 On Monday, ... call to industry to share solutions for the Biometric ... U.S. Customs and Border Protection (CBP), explains that CBP ... are departing the United States , ... and to defeat imposters. Logo - ...
(Date:6/9/2016)... innovation leader in attendance control systems is proud to announce the introduction of fingerprint ... sure the right employees are actually signing in, and to even control the opening ... ... ... Photo ...
(Date:6/2/2016)... NEW YORK , June 2, 2016   The ... (Weather), is announcing Watson Ads, an industry-first capability in which ... advertising, by being able to ask questions via voice or ... Marketers have long ... with the consumer, that can be personal, relevant and valuable; ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... A person commits a crime, and the detective ... the criminal down. An outbreak of foodborne illness ... (FDA) uses DNA evidence to track down the bacteria that ... It,s not. The FDA has increasingly used a complex, cutting-edge ... illnesses. Put as simply as possible, whole genome sequencing is ...
(Date:6/23/2016)... Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young ... cancer. Members of the Class of 2016 were selected from a pool of ... More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the Industry Network ... Supplyframe Design Lab . Located in Pasadena, Calif., the Design Lab’s mission is ... projects are designed, built and brought to market. , The Design Lab is ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology: